| Similar Articles |
|---|
 |
Chemistry World
October 19, 2015
Philippa Matthews |
BMS agrees $1.7bn immuno-oncology collaboration Bristol-Myers Squibb has entered into a worldwide license and collaboration with Five Prime Therapeutics to develop and commercialize Five Prime's colony stimulating factor 1 receptor (CSF1R) antibodies.   |
Chemistry World
August 27, 2014
Phillip Broadwith |
Clinical collaborations drive cancer immunotherapy A joint clinical trial agreement between Merck & Co and Pfizer is the latest in a rather tangled web of tie-ups between companies with cancer drugs that harness patients' immune systems. |
Chemistry World
June 12, 2014
Andy Extance |
Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors. |
Chemistry World
July 31, 2014
Phillip Broadwith |
AstraZeneca stocks respiratory and cancer pipelines AstraZeneca has agreed to buy Spanish firm Almirall's respiratory drug assets for $875 million up front, plus up to $1.2 billion in performance milestone payments. |
Chemistry World
July 3, 2015
Andy Extance |
Pharma queues up for checkpoint inhibitor collaborations Amid fierce rivalries over the latest generation of cancer treatments, drug makers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry. |
Chemistry World
October 2, 2012
Andrew Turley |
Merck & Co $460m ion channel deal Merck & Co has struck a $460 million deal for rights to certain drug candidates developed by Belgian pharma company Ablynx. Merck will get rights to the monoclonal antibodies found to target a voltage gated ion channel. |
The Motley Fool
August 31, 2011
Brian Orelli |
Antibodies: They're Not Just for Fighting Infection Anymore Therapeutic antibodies have continued to evolve since the first, OKT3, was approved back in 1986. Biotech investors had better pay attention, lest the technology passes them by. |
Chemistry World
February 4, 2014
Phillip Broadwith |
Merck & Co doubles up on Ablynx research deal This collaboration will focus on nanobodies (antibody fragments) directed against cancer. |
Chemistry World
December 21, 2015
Katrina Kramer |
BioAtla and Pfizer to collaborate on antibody research BioAtla and Pfizer will share expertise to develop tumor-targeting antibodies chemically bound to cytotoxic drugs. |
Chemistry World
September 25, 2013
Phillip Broadwith |
Nanobody inflammation drug attracts Abbvie Belgian biotech firm Ablynx has agreed a global licensing deal with Abbvie for its nanobody drug candidate ALX-0061. |
The Motley Fool
June 22, 2004
Charly Travers |
Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline. |
Chemistry World
December 17, 2015
Sarah Houlton |
Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market. |
Chemistry World
June 12, 2014
Philli Broadwith |
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion. |
Chemistry World
February 24, 2015
Phillip Broadwith |
B-MS bolsters immuno-oncology with pair of deals In a bid to bolster its pipeline of immuno-oncology drugs, Bristol-Myers Squibb has agreed to buy US biotech firm Flexus Biosciences in a deal worth up to $1.25 billion |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
November 11, 2009
Brian Orelli |
Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
The Motley Fool
May 9, 2006
Brian Gorman |
No Quick Fix for Merck Two biotech purchases won't bolster the drug giant's pipeline, but they promise a longer-term payoff. Investors will have to be patient. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
Chemistry World
June 5, 2015
Rebecca Trager |
BMS sues executive for joining rival company Bristol-Myers Squibb has filed a lawsuit against a former executive who quit suddenly last month to work for a direct competitor, AstraZeneca. |
Pharmaceutical Executive
November 1, 2014
Josh Baxt |
2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
The Motley Fool
July 14, 2011
Brian Orelli |
Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial. |
Pharmaceutical Executive
November 1, 2012 |
Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes. |
Pharmaceutical Executive
November 1, 2013
Ben Comer |
2014 Pipeline Report: The Sprint to Value Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters. |
The Motley Fool
June 29, 2011
Brian Orelli |
Doubling Up in Biotech Lilly hits multiple targets with one drug. |
Pharmaceutical Executive
December 1, 2008
Ron Feemster |
The 2008 Pipeline Report We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond. |
The Motley Fool
June 29, 2011
Brian Orelli |
4 Immunotherapies to Watch Just don't go all-in. |
Chemistry World
July 8, 2014
Phillip Broadwith |
First of a new breed of anticancer antibodies approved in Japan Ono pharmaceuticals' Opdivo (nivolumab) has been approved for treating melanomas where surgery is impossible. |
Chemistry World
January 6, 2015
Sarah Houlton |
Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion. |
The Motley Fool
March 21, 2007
Brian Lawler |
New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
The Motley Fool
December 27, 2010
Brian Orelli |
Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline. |
The Motley Fool
September 18, 2007
Brian Orelli |
Another Partnership for Personalized Medicine Celera gets a contract to design a companion diagnostic test for Merck. Investors, take note. |
Chemistry World
December 22, 2011
Sarah Houlton |
Pharma braces for patent cliff impact It remains to be seen quite how far Lipitor sales will fall. Ranbaxy has six months of exclusivity for generic competition. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
May 15, 2006
Brian Gorman |
AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note. |
Chemistry World
July 25, 2008
Olivia Walker |
Engineered antibodies could cut chemotherapy risks US scientists have cut the side-effects of cancer treatment in animal trials by carefully controlling the number of drug molecules attached to the antibodies used for chemotherapy. |
The Motley Fool
December 12, 2007
Brian Orelli |
What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010. |
Chemistry World
October 4, 2013
Andy Extance |
Amid huge cuts, Merck vows research focus US-based drug giant Merck & Co will cut 8,500 more jobs as it seeks to cut costs by $2.5 billion |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
Bio-IT World
March 2006
Salamone & Davies |
Merck President Touts Technology Benefits Peter Kim, president of Merck Research Laboratories, says that small changes in the drug discovery and development process can yield significant benefits in bringing new drugs to market. |
Chemistry World
January 6, 2014
Sarah Houlton |
Weathering the storm Pharma is in the middle of a strategic crisis, if a report published at the start of 2013 by Roland Berger Strategy Consultants is to be believed. |
